Invention Grant
- Patent Title: Pharmaceutical composition containing DUSP1 inhibitor
-
Application No.: US16603993Application Date: 2018-02-28
-
Publication No.: US11147807B2Publication Date: 2021-10-19
- Inventor: Seong Eon Ryu , Tae Hyun Park , Kwang Hwan Lee , Ju Seop Kang , Shin Hee Kim , Kyoung Tae Nam , Hyeon Kyu Lee
- Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
- Applicant Address: KR Seoul; KR Daejeon
- Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY,KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
- Current Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY,KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
- Current Assignee Address: KR Seoul; KR Daejeon
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2017-0046102 20170410
- International Application: PCT/KR2018/002477 WO 20180228
- International Announcement: WO2018/190511 WO 20181018
- Main IPC: A61K31/47
- IPC: A61K31/47 ; A61P25/24 ; A61P35/00

Abstract:
The present invention relates to a pharmaceutical composition comprising a DUSP1 inhibitor. The pharmaceutical composition comprising the DUSP1 inhibitor according to the present invention can solve the problems of inhibitors that target the active site because it inhibits DUSP1 by an allosteric inhibitory mechanism, and is effective for preventing or treating diseases involving DUSP1 enzymes, for example, a cancer such as a liver cancer, a breast cancer and a pancreatic cancer, a hepatitis C, and a depression. In particular, the DUSP1 inhibitor according to the present invention is very effective in treating a depression because it directly acts on neuronal growth.
Public/Granted literature
- US20200155537A1 PHARMACEUTICAL COMPOSITION CONTAINING DUSP1 INHIBITOR Public/Granted day:2020-05-21
Information query